GlaxoSmithKline Says ViiV, Halozyme Signed Deal for Drug-Delivery Technology
June 22 2021 - 2:37AM
Dow Jones News
By Adria Calatayud
GlaxoSmithKline PLC said Tuesday that ViiV Healthcare, the
specialist HIV company in which it holds a majority stake, has
signed a licensing agreement that gives it exclusive access to
Halozyme Therapeutics Inc.'s Enhanze drug-delivery technology.
The collaboration will allow ViiV to develop long-acting
medicines for HIV, GlaxoSmithKline said. Under the agreement, ViiV
will make an upfront payment of $40 million to Halozyme for am
exclusive license to four HIV small and large molecule targets and
is obligated to make potential future payments of up to $175
million, subject to hitting some development and commercial
milestones, GlaxoSmithKline said.
The U.K. pharmaceutical giant said ViiV plans to start the first
experiments with the technology by the end of 2021.
ViiV is majority-owned by GlaxoSmithKline, with Pfizer Inc. and
Shionogi & Co. as shareholders.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
June 22, 2021 02:31 ET (06:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Apr 2023 to Apr 2024
